Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) | PAR 22 222

Opportunity Information: Apply for PAR 22 222

The National Institutes of Health (NIH) funding opportunity titled "Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)" (Funding Opportunity Number PAR 22-222) is a discretionary grant program designed to push forward the development of new multipurpose prevention technologies, or MPTs. In practical terms, NIH is looking to support products and approaches that can prevent more than one sexual and reproductive health outcome at the same time, with a strong emphasis on combinations that address HIV prevention alongside pregnancy prevention and/or prevention of other sexually transmitted infections (STIs). The FOA is structured to encourage innovations that people can realistically adopt and use, whether the method is taken on-demand, used around the time of sexual activity (event-driven), or delivered in a long-acting way, including both systemic approaches (affecting the whole body) and non-systemic approaches (acting locally).

A central focus of the opportunity is expanding the pipeline of MPT options that work for different bodies, needs, and situations. NIH explicitly notes interest in MPTs relevant to both cisgender and transgender males and females, and across all ages. The prevention targets supported by this FOA include several configurations: technologies that prevent HIV infection and pregnancy (including hormonal and non-hormonal contraceptive strategies), technologies that prevent STIs and pregnancy, technologies that prevent multiple non-HIV STIs, and combined HIV/STI prevention approaches. This framing signals that NIH is not limiting applicants to a single "ideal" combination, but rather is trying to broaden the set of viable multipurpose products that could improve public health outcomes by reducing the need for separate, single-purpose interventions.

The FOA supports a wide range of research and development activities that sit in the translational space between early concept and more mature product development. On the biomedical side, applications may include pharmacokinetic (PK) studies (how a drug moves through the body), pharmacodynamic (PD) studies (what the drug does to the body and pathogens), safety assessments, and drug-drug interaction (DDI) studies, which are especially important for combination products or for users who may be taking other medications. The announcement also highlights drug development and formulation science, with animal model testing used where appropriate to support development decisions. This combination indicates NIH is looking for proposals that are grounded in practical product development milestones, not just exploratory biology, and that can generate evidence needed to de-risk a technology and move it closer to clinical readiness.

In addition to laboratory and preclinical work, the FOA also values research that addresses the human factors that often determine whether prevention technologies succeed in the real world. It supports biobehavioral and behavioral/social studies aimed at understanding what potential users want and will consistently use. In particular, NIH calls out interest in rheological and biophysical factors, which for MPT products can include characteristics such as look and feel, texture, viscosity, how the product spreads or dissolves, perceived and actual comfort, confidence in effectiveness, safety perceptions, and duration of action. These aspects can matter as much as clinical efficacy when it comes to adherence and long-term uptake. The FOA also welcomes broader behavioral and social research designed to identify barriers and facilitators to adoption, recognizing that partner dynamics, stigma, access, convenience, and trust in medical systems can strongly influence real-world use.

The funding mechanism is an NIH R01, and the listing notes "Clinical Trial Optional," meaning applicants may propose clinical trials if they are appropriate for the stage of development and the specific aims, but a clinical trial is not required. The program sits within NIH health-related funding activity categories and is associated with CFDA numbers 93.242, 93.855, and 93.865. While the specific award ceiling and number of expected awards are not provided in the supplied source data, the overall structure indicates a typical NIH research project grant with expectations for a coherent, hypothesis- and milestone-driven plan, aligned with product development logic and supported by strong preliminary rationale.

Eligibility is broad and intentionally inclusive, spanning many types of organizations that can contribute to MPT development. Eligible applicants include state, county, city or township, and special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; nonprofit organizations with or without 501(c)(3) status (excluding institutions of higher education where noted); for-profit organizations other than small businesses; small businesses; and various tribal governments and organizations. The FOA also explicitly mentions additional eligible applicant categories such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations). This breadth suggests NIH is encouraging multidisciplinary partnerships and acknowledging that MPT innovation can come from academic labs, product developers, clinical research groups, community-based organizations with deep user insight, and international teams working in settings with high prevention needs.

Key administrative details from the source data include the NIH as the sponsoring agency, the opportunity category listed as discretionary, and the original closing date recorded as 2023-05-09, with a creation date of 2022-08-04. Overall, this FOA is best understood as a development-oriented NIH program aimed at building the next wave of prevention products that combine protection goals, offer flexible dosing and delivery options (on-demand through long-acting), and incorporate user-centered evidence so that the resulting technologies are not only scientifically sound but also realistic for people to choose and stick with in everyday life.

• The National Institutes of Health in the health, income security and social services sector is offering a public funding opportunity titled "Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242, 93.855, 93.865.
• This funding opportunity was created on 2022-08-04.
• Applicants must submit their applications by 2023-05-09. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 22 222

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: